Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

Krazati and Erbitux show significant efficacy in KRAS G12C-mutant mCRC, with ORR of 34% (BICR) and 43% (investigator review). The disease control rate was 85% (BICR) and 86% (investigator review), ...

At ASCO, Eli Lilly, Genfleet Therapeutics and InxMed all presented new clinical data on KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), going after the same mutation and indication as ...

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Vectibix (panitumumab), for treating KRAS G12C-mutated metastatic colorectal cancer (mCRC). The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult ...

The approval was based on results from CodeBreaK 300, a phase 3, multicenter, open-label, randomized trial that enrolled 160 patients who had not had previous treatment with a KRAS G12C inhibitor.

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover ...

Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination has received approval from the US Food and Drug Administration (FDA) to treat adults with Kirsten rat sarcoma virus gene (KRAS) ...